Work

353P Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.301

Authors: R. Scheel, G.M. Choong, R. Koch, S.K. Yadav, A. Karki, R. Rao, N.J. Boddicker, C. Hu, J. Na, V. Kaggal, S. Murphy, K.V. Giridhar, S. Yasir, M.P. Goetz, F.J. Couch, S. Yadav

Institutions: Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), Mayo Clinic Health System

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Mayo Clinic, Eli Lilly and Company, AstraZeneca, Gilead Sciences, Regeneron Pharmaceuticals, Menarini Silicon Biosystems, Puma Biotechnology, ZonMw, National Institutes of Health, National Cancer Institute

Award: Mayo Clinic Breast Cancer SPORE

OpenAlex ID: W4402561238

FWCI: 1.155

Cites:

Cited by: 4

Related to: 10